Review of palonosetron: emerging data distinguishing it as a novel 5-HT₃ receptor antagonist for chemotherapy-induced nausea and vomiting

Bibliography

• del Giglio A, Soares HP, Caparroz C, Castro PC. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer 2000;89:2301-8
   PubMed Web of Science ®Google Scholar
• Jordan K, Hinker A, Grothey A, Schmoll HJ. Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis. Support Care Cancer 2005;13:26-31
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Deuson RR, Mavros P, Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004;100:2261-8
   PubMed Web of Science ®Google Scholar
• FDA Product information. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=ALOXI. [Last accessed 17 August 2009]
   Google Scholar
• Eisenberg P, Figueroa-Vadillo J, Zamora R, Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473-82
   PubMed Web of Science ®Google Scholar
• Gralla R, Lichinitser M, Van Der Vegt S, Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-7
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ, The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-19
   PubMed Web of Science ®Google Scholar
• Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Addition of the neurokinin-1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-8
   PubMed Web of Science ®Google Scholar
• Antiemesis. NCCN clinical practice guidelines in oncology. V.3. 2009. Available from: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. [Last accessed 10 May 2009]
   Google Scholar
• MASCC home page. Available from: www.mascc.org
   Google Scholar
• Martin M. The severity and pattern of emesis following different cytotoxic agents. Oncology 1995;53(Suppl 1):26-31
   Google Scholar
• Del Favero A, Roila F, Tonato M. Reducing chemotherapy induced nausea and vomiting. Current perspectives and future possibilities. Drug Saf 1993;9:410-28
   PubMed Web of Science ®Google Scholar
• Huang JQ, Zheng GF, Deuson R, Do 5-hydroxytryptamine3 receptor antagonists (5-HT3) improve the antiemetic effect of dexamethasone for preventing delayed chemotherapy-induced nausea and vomiting (CINV)? A meta-analysis of randomized controlled trials. J Clin Oncol 2004;22(14S): abstract 6037
   Google Scholar
• Herrstedt antiemetics: an update and the MASCC guidelines applied in clinical practice. J Nat Clin Pract Oncol 2008;5:32-43
   PubMedGoogle Scholar
• Geling O, Eichler H-G. Should 5-hydroxytryptamine-3 receptor antagonists be. administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005;23:1289-94
   PubMed Web of Science ®Google Scholar
• Aapro MS, Alberts DS. High-dose dexamethasone for prevention of cisplatin-induced vomiting. Cancer Chemother Pharmacol 1981;7:11-4
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 2000;18:3409-22
   PubMed Web of Science ®Google Scholar
• Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Ann Oncol 1998;9:811-19
   Google Scholar
• Gralla RJ, Osoba D, Kris MG, American Society of Clinical Oncology: evidence-based, clinical practice guidelines. Recommendations for the use of antiemetics. J Clin Oncol 1999;17:2971-97
   PubMed Web of Science ®Google Scholar
• Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs 1996;52:639-48
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Kris MG, Grunberg SM, Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-9
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Osoba D, Hesketh PJ, Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity – an update. Support Care Cancer 2005;13:80-4
   PubMed Web of Science ®Google Scholar
• Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17:20-8
   PubMed Web of Science ®Google Scholar
• Saito M, Aogi K, Sekine I, Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009;10:115-24
   PubMed Web of Science ®Google Scholar
• Aapro MS, Grunberg SM, Manikhas GM, A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-9
   PubMed Web of Science ®Google Scholar
• Stoltz R, Cyong JC, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in US and Japanese healthy subjects. J Clin Pharmacol 2004;44:520-31
   PubMed Web of Science ®Google Scholar
• Stoltz R, Parisi S, Shah A, Macciocchi A. Pharmacokinetics, metabolism and excretion of intravenous [14C]-palonosetron in healthy human volunteers. Biopharm Drug Dispos 2004;25:329-37
   PubMed Web of Science ®Google Scholar
• McNulty R. Are all 5-HT3 receptor antagonists the same? J Natl Compr Canc Netw 2007;5:35-43
   PubMedGoogle Scholar
• Wong EH, Clark R, Leung E, The interaction of RS25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 1995;114:851-9
   PubMed Web of Science ®Google Scholar
• Rojas C, Stathis M, Thomas AG, Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 2008;107:469-78
   PubMed Web of Science ®Google Scholar
• Rojas C, Thomas AG, Alt J, Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 2010;626:193-9
   PubMed Web of Science ®Google Scholar
• Musso M, Scalone R, Bonanno V, Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care Cancer 2009;17:205-9
   PubMed Web of Science ®Google Scholar
• Musso M, Scalone R, Crescimanno A, Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant 2010;45:123-7
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Brames MJ, Dreicer R, Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 2007;15:1293-300
   PubMed Web of Science ®Google Scholar
• De Mulder PH, Seynaeve C, Vermorken JB, Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med 1990;113:834-40
   PubMed Web of Science ®Google Scholar
• Fox SM, Einhorn LH, Cox E, Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 1993;11:2391-5
   PubMed Web of Science ®Google Scholar
• Bubalo JS, Ta VH, Donner AL, A phase II, randomized, double-blind clinical trial of palonosetron (PALO) for the prevention of emesis in patients receiving high-dose melphalan chemotherapy prior to stem cell transplant (SCT) [abstract CS19]. J Oncol Pharm Pract 2008;14:81-2. Available from: http://opp.sagepub.com
   Google Scholar
• Einhorn LH, Rapoport B, Koeller J, Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 2005;13:112-16
   PubMed Web of Science ®Google Scholar
• Hajdenberg J, Grote T, Yee L, Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. J Support Oncol 2006;4:467-71
   PubMedGoogle Scholar
• Giuliani F, Cilentib G, Nugnesa I, Palonosetron for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic adjuvant folfox-4 regimen in colorectal cancer (CRC) patients: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (GOIM). Eur J Cancer Suppl 2008;6:102-6
   Web of Science ®Google Scholar
• Maemondo M, Masuda N, Sekine I, A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. Ann Oncol 2009;20:1860-6
   PubMed Web of Science ®Google Scholar
• Segawa Y, Aogi K, Inoue K, A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy. Ann Oncol 2009;20:1874-80
   PubMed Web of Science ®Google Scholar
• Grote T, Hajdenberg J, Cartmell A, Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Suppor Oncol 2006;4:403-8
   PubMedGoogle Scholar
• Grunberg SM, Dugan M, Muss H, Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 2009;17:589-94
   PubMed Web of Science ®Google Scholar
• Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 2008;112:2080-7
   PubMed Web of Science ®Google Scholar
• Morganroth J, Parisi S, Moresino C, High dose Palonosetron does not alter ECG parameters including QTc interval in healthy subjects: results of a dose-response, double-blind, randomized, parallel E14 study of palonosetron vs. moxifloxacin or placebo. Eur J Cancer 2007;(Suppl 5):158
   Google Scholar
• European Product Information. 29/01/2009 Aloxi-H-C-563-II-13. Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/aloxi/aloxi.htm. [Last accessed 17 August 2009]
   Google Scholar
• Navari R, Einhorn L, Loehrer P, A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer 2007;15:1285-91
   PubMed Web of Science ®Google Scholar
• Navari RM, Einhorn LH, Loehrer PJ, A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 2005;13:529-34
   PubMed Web of Science ®Google Scholar
• Kris MG, Hesketh PJ, Somerfield MR, American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-47
   PubMed Web of Science ®Google Scholar
• Raftopoulos H, Bria E, Gralla RJ, Is there a preferred dose of palonosetron? Results of abstracted data meta-analysis of all 8 randomized double-blind studies and the impact on guideline considerations. J Clin Oncol 2009;27(Suppl 15): abstract 9636
   Web of Science ®Google Scholar
• Grunberg SM, Voisi D, Zufferli M, Piraccini G. Oral palonosetron is as effective as intravenous palonosetron: a Phase 3 dose ranging trial in patients receiving moderately emetogenic chemotherapy [abstract 1143]. Eur J Cancer Suppl 2007;5:155
   Google Scholar